CONFERENCE SERIES: Biomarkers and Diagnostics
Recorded at: Molecular Medicine Tri-Conference
Digital Course: Understanding EMT: Mechanisms and Metastasis to MET
About this Product:
Epethelial Mesenchymal Transition (EMT) plays a critical role in cancer cells, but understanding of its mechanisms is incomplete. EMT causes cells to develop increased motility, invasiveness, and greater resistance to apoptosis. These changes make the cells more like stem cells, allowing them to self renew. This course provides a framework of the underlying molecular mechanisms while addressing stem cells, and cancer progression, cMET and their activity as anti-metastasis agents, and the Mesenchymal-Epethelial Transition (MET) as an essential process for tumor re-initiation, colonization, and metastasis.
About this Product:
Over 72 Minutes
Site License: $1380
Agenda At A Glance:
EMT, Stem Cells and Cancer Progression
Sendurai A. Mani, Ph.D. , Assistant Professor, Department of Molecular Pathology; Co-Director, Metastasis Research Center, M.D. Anderson Cancer Center
More than 80% of human cancers are carcinomas (which originate in epithelial tissues), and the majority of the patients who succumb to carcinomas do so due to the development of metastases, therapy resistance or tumor relapse. Recent evidence shows that cancer stem cells (CSCs) can drive these clinical phenotypes and that CSCs can be generated via the activation of Epithelial-Mesenchymal Transition (EMT). The role of EMT in the above disease states will be discussed further.
Biography: Dr. Sendurai Mani received his training from the Whitehead Institute at MIT and is currently an Assistant Professor doing research at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. His lab is interested in understanding the biology of cancer progression, especially the role of cancer stem cells and the embryonic developmental process known as "Epithelial-Mesenchymal Transition (EMT) in cancer progression.
The Mesenchymal-Epithelial Transition (MET) As An Essential Process For Tumor Re-Initiation, Colonization and Metastasis
Fredika M. Robertson, Ph.D., Professor, Department of Experimental Therapeutics, Center for Targeted Therapy, Translational Therapeutics Laboratory, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, M.D. Anderson Cancer Center
Very aggressive tumor types often paradoxically retain epithelial characteristics, exhibit stem cell characteristics, and have a high degree of plasticity, which are signatures of the mesenchymal-epithelial transition (MET). These tumor types are capable of tumor colonization at numerous distant organ sites, with development of rapid metastasis. This discussion will focus on characteristics of the process of MET and therapeutic targeting of this process to abrogate tumor metastasis.
Biography: Dr. Fredika Robertson received her Ph.D. degree in 1986 in the subject area of Experimental Therapeutics from the Roswell Park Cancer Institute Grace Cancer Drug Center, State University of New York at Buffalo.
She has pursued an academic career for the past 25 years focused on translational cancer research, specifically identifying molecular mechanisms of breast cancer metastasis and therapeutic approaches to target this process, with a goal of accelerating newly emerging therapeutics for their evaluation in clinical trials for patients with very aggressive cancers for whom there are few therapeutic options. She is currently Professor in the Department of Experimental Therapeutics, Center for Targeted Therapy at the University of Texas MD Anderson Cancer Center and is Director of the Laboratory for Translational Therapeutics in the inflammatory Breast Cancer Research Program and Clinic.
About the Conference:
Molecular Med Tri-Con is a five day event where over 3,000 attendees participate in interactive lectures, discussions, various receptions which offer numerous networking and learning opportunities. The Tri-Conference is the leading scientific event to hear differing views and perspectives on poignant issues facing you and our industry today.